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Abstract
Digital Pathology (DP) is a platform which has the potential to develop a truly integrated and global pathology
community. The generation of DP data at scale creates novel challenges for the histopathology community in man-
aging, processing, and governing the use of these data. The current understanding of, and confidence in, the legal
and ethical aspects of DP by pathologists is unknown. We developed an electronic survey (e-survey) comprising of
22 questions, which was developed with input from the Royal College of Pathologists (RCPath) Digital Pathology
Working Group. The e-survey was circulated via e-mail and social media (Twitter) through the RCPath Digital
Pathology Working Group network, RCPath Trainee Committee network, the Pathology image data Lake for Analyt-
ics, Knowledge and Education (PathLAKE) digital pathology consortium, National Pathology Imaging Co-operative
(NPIC), local contacts, and to the membership of both The Pathological Society of Great Britain and Ireland and the
British Division of the International Academy of Pathology (BDIAP). Between 14 July 2020 and 6 September 2020,
we collected 198 responses representing a cross section of histopathologists, including individuals with experience
of DP research. We ascertained that in the UK, DP is being used for diagnosis, research, and teaching, and that the
platform is enabling data sharing. Our survey demonstrated that there is often a lack of confidence and understand-
ing of the key issues of consent, legislation, and ethical guidelines. Of 198 respondents, 82 (41%) did not know
when the use of digital scanned slide images would fall under the relevant legislation and 93 (47%) were ‘Not con-
fident at all’ in their interpretation of consent for scanned slide images in research. With increasing uptake of DP, a
working knowledge of these areas is essential but histopathologists often express a lack of confidence in these
topics. The need for specific training in these areas is highlighted by the findings of this study.
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Introduction
The past 20 years have witnessed the growing
digitalisation of histopathology services as a result of
developments in whole slide image (WSI) scanning,
storage, and analysis [1]. The implementation of Dig-
ital Pathology (DP) has been relatively slow in the
United Kingdom (UK), although rapid changes are
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on the horizon [2,3]. Currently, there are 41 pathology
units in the UK, with approximately 1256 consul-
tants. A UK 2018 survey found that 60% of pathol-
ogy units have access to a DP scanner [3]. Following
recent investment in DP infrastructure, five Artificial
Intelligence (AI) Centres of Excellence have been
established in the UK, aiming to develop the coun-
try’s DP and imaging expertise. These are: the Indus-
trial Centre for AI Research in Digital Diagnostics
(I-CAIRD) based in Glasgow, the London Medical
Imaging and Artificial Intelligence Centre for Value-
Based Healthcare, the National Consortium of In-
telligent Medical Imaging (NCIMI) in Oxford, the
National Pathology Imaging Co-operative (NPIC)
based in Leeds, and the Pathology image data Lake
for Analytics, Knowledge and Education (PathLAKE)
based in Coventry.
The adoption of DP is part of the strategy set out by
the NHS Long Term Plan for digitally enabled care
and the UK Government’s Industrial Life Sciences
Strategy [4,5]. Stakeholders relevant to the digitali-
sation of pathology in the UK include The National
Data Guardian, The Information Commissioner’s
Office (ICO), Alan Turing Institute, Health Data
Research UK, Care Quality Commission, Public Health
England, NHS Digital, and NHSX [6–13]. Interna-
tionally, the World Health Organisation (WHO), in
partnership with the International Telecommunica-
tion Union (ITU), has established a Focus Group on
Artificial Intelligence for Health (FG-AI4H) with the
aim of identifying opportunities for standardisation
and applications of AI to health issues on a global
scale [14].
DP involves the creation of digital images by using
a scanning device to provide high-resolution images
that can be viewed on a platform. This provides a
stage platform for developing and utilising AI algo-
rithms, for recognising subtle patterns in tissue to
assist diagnosis or derive novel insights into disease
[15–18]. Generation of data from DP creates chal-
lenges for the histopathology community with regard
to data management, processing, and security. The UK
Government has stated that protecting patient data is a
legal requirement of paramount importance [6,19].
This is echoed globally, with guidelines, policies, and
legislations aiming to ensure appropriate application of
DP (Table 1).
Literature discussing the potential benefits of DP/AI
rarely mention the ethical and legal considerations of
access to, and processing of, patient data [45–51].
Advice/guidance on medical ethics and data gover-
nance exists, although the depth to which these topics
are explored varies significantly (Table 1). This is
complicated by WSI data often being generated pri-
marily for diagnostic purposes but having other uses,
i.e. teaching and research. This complex situation is
compounded when collaborating with industry part-
ners, and by political uncertainty such as the UK’s
recent withdrawal from the European Union (EU) and
working across jurisdictions. It is unclear whether pre-
sent frameworks and guidelines are useful to histopa-
thologists or if there is a need for additional
pathology-focused guidelines [6,28,52–55].
In this paper, we present the results of an electronic
survey (e-survey) aiming to evaluate UK histopatholo-
gists’ current levels of understanding of, and confi-
dence with, the legal and ethical aspects of DP and
their perceived training needs. We evaluate whether
the rise of DP has created this need with the move
from tissue-based work (where there is experience
with legislation) to image/data-centred practice with
different considerations; although targeted specifically
at DP rather than AI, we also discuss relevant over-
lapping issues.
Materials and methods
We developed an e-survey comprising 22 questions
using the online platform ‘SurveyMonkey’ (www.
surveymonkey.co.uk). The questionnaire (supplemen-
tary material, Appendix S1) was developed with input
from the Royal College of Pathologists (RCPath) Digi-
tal Pathology Working Group.
Information provided to gain consent included:
study purpose, approximate completion time, confir-
mation of anonymity, and details of principal in-
vestigators. ‘SurveyMonkey’ collected the data; their
privacy policy was present on their website at the time
of completion. Consent was implicit by completion of
the survey. No ethics approval was required.
Initially, a pilot e-survey was developed to assess
the usability and technical functionality of the e-survey
and tested by a pre-selected cohort (three consultant
histopathologists and one specialty trainee) as a closed
survey. The e-survey was structured with single
sequential questions and question formats included:
forced-choice, Likert scales, yes/no options, and
open-ended/free text questions. The topics were:
Demographics, Background, Training, Guidelines and
Legislation, Consent, and Data sharing. Participants
could review and amend answers prior to submission.
Following the pilot e-survey, questions were rephrased
to avoid testing specific knowledge and to gauge gen-
eral understanding.
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Table 1. DP – relevant guidelines, position papers, regulations, and legislation relating to the management/use of data generated
through WSI (amended from García-Rojo [20] and Chong et al [21], non-exhaustive list).
Country/region Guideline/legislation Comments
UK 2018: Royal College of Pathologists – Best
practice recommendations for implementing
DP
Provides ‘an overview of the technology involved in DP and of the
currently available evidence on its diagnostic use, together with
practical advice for pathologists on implementing DP’ [22]
2018: UK Government – The DPA Stipulates how personal information is used by organisations,
businesses, or the government. It is the UK’s implementation of
the GDPR [23]
2018: UK Government – NHS Data Opt-Out Introduced to enable patients to opt out from the use of their data
for research or planning purposes in line with the
recommendations of the National Data Guardian [24]
2018: UK Government – Code of Conduct for
Data Driven Health and Care Technology
A guide to good practice for the use of digital technology in health
and care. The guide provides a set of principles that state what is
expected from suppliers and users of data-driven technologies [19]
2019: UK Government – NHSX Artificial
Intelligence How to Get it Right
Provides an overview of the current state of play of data-driven
technologies within the health and care system in the UK [6]
Ongoing: Office for National Statistics (ONS):
Principles for Data Initiatives
ONS is the UK’s largest independent producer of official statistics,
responsible for collecting and publishing statistics related to
population and society. The Principles for Data Initiatives is a
section of the ONS Data Strategy, which states their
fundamental principles and standards to promote public trust in
their data handling [25]
Ongoing: Common Law Duty of Confidentiality Common law (case law) is law that has developed through the
courts making decisions in cases on legal points and creating
binding precedents in contrast to statutory law which is
determined by acts of parliament. It is the legal obligation for
confidentiality; when personal information is shared in
confidence, it must not be disclosed without some form of legal
authority or justification [26]
EU 2021: EU: Medical Devices Regulation Regulation stating that software will be considered a medical
device if it forms part, or is an accessory, of a medical device or
where it constitutes standalone software, has a medical purpose,
and the processing of the data goes beyond mere storage,
archiving, communication, or simple search [27]
2018: EU: GDPR Regulation drafted and passed by the EU for the processing of
personal information, either within the EU or information related
to people in the EU [28]
2016: EU – US Privacy Shield It was a framework for regulating transatlantic exchanges of
personal data for commercial purposes between the EU and US.
In 2020, a court issued that the framework no longer provided
adequate safeguards so is now defunct [29]
The United States of America 2021: Healthcare and Public Health Sector
Coordinating Council (HSCC) Position Paper
The HSCC Joint Cybersecurity Working Group is a standing working
group of the HSCC composed of more than 300 industry and
government organisations working together to develop strategies
to address emerging and ongoing cybersecurity challenges to the
health sector. They do state that the federal and state
regulations have not kept in step with the rapid and widespread
adoption of telehealth technologies across the country. Currently,
there is no single federal agency with authority to establish and
enforce privacy and security requirements for the entire
telehealth ecosystem [30]
2021: College of American Pathologists –
Validating Whole Slide Imaging Systems for
Diagnostic purposes in Pathology, Guidelines
Update
Guidelines stating if WSI is used for diagnostic or other related
clinical purposes, procedures must be in place that ensure sites
using WSI provide reasonable and expected confidentiality and
data security, in both data storage and data transmission [31]
2020: US Food and Drug administration (FDA) –
Enforcement Policy for remote DP devices
during the Coronavirus Disease 2019 Public
Health Emergency
Previously, FDA-approved WSI devices were not cleared for home
use or categorised as waived by FDA, so limited to use in clinical
laboratories and their healthcare settings. In March 2020, the
Centers for Medicare & Medicaid Services (CMS) issued a
memorandum, describing its exercise of enforcement discretion
(Continues)
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Following satisfactory completion of the pilot e-sur-
vey, the open e-survey web link was circulated via
social media (Twitter) and e-mail through the RCPath
Digital Pathology Working Group network, RCPath
Trainee Committee network, the PathLAKE digital
pathology consortium, National Pathology Imaging
Table 1. Continued
Country/region Guideline/legislation Comments
to ensure pathologists may review pathology slides and images
remotely [32]
2020: American Telemedicine Association (ATA).
Policy Principles
Policies highlighting the importance of protection of patient privacy
and cybersecurity risks along with the importance of ensuring
safe transfer across state lines. Not specific for DP [33]
2019 (initially authorised 2017): US FDA WSI device authorised for marketing in the US with a second
system cleared for use in 2019 [34]
2018: ATA Clinical Guidelines for Telepathology Guidelines state that all data transmission used in telepathology
should be secured through the use of encryption that meets
recognised standards. The ATA also recommends that protected
health information and other confidential data only be backed up
to or stored on secure data storage locations. Cloud services
unable to achieve compliance should not be used for personal
health information or confidential data [35]
2015: United States Government: Cybersecurity
Information Sharing Act
Established a mechanism for cybersecurity information sharing
among private sector and federal government entities – provides
a set of cybersecurity best practices that should be used in the
protection of telehealth and telemedicine systems and services
[36]
1996: US Department of Health and Human
Services. Health Insurance Portability and
Accountability Act (HIPAA)
The act mandates data security and privacy controls to keep
medical information safe. The Department of Health and Human
Services (HHS) publishes the HIPAA privacy rule, the HIPAA
security rule, and the HIPAA breach notification rule [37]
Canada 2019: Office of the Privacy Commissioner of
Canada – The Personal Information Protection
and Electronic Documents Act (PIPEDA)
The PIPEDA applies to private sector organisations across Canada
that collect, use, or disclose personal information in the course
of a commercial activity. Personal information relating to
hospitals can also be covered by provincial laws [38]
2014: Canadian Association of Pathologists –
Guidelines for establishing a telepathology
service for anatomical pathology using WSI
The objective is to provide Canadian pathologists with baseline
information on how to implement and use relevant platforms.
Guidelines cover privacy and security, document, and archiving
and liability [39]
2005: Canadian Association of Pathologists –
Code of ethics for storage and transmission of
electronic laboratory data
A voluntary code based on the work of the Guidelines Governing
the Protection of Privacy and Transborder Flows of Personal Data,
created by the international Organization for Economic
Cooperation and Development (OECD) [40]
Germany 2018: Professional Association of German
Pathologists – Digital Pathology in
Diagnostics – reporting on digital images
Purpose of the guidelines is to direct the framework on how to
implement virtual microscopy in routine diagnosis in Germany
and includes the topic of data security [41,42]
Australasia 2015: The Royal College of Pathologists of
Australasia (RCPA) – Guidelines for Digital
Microscopy in Anatomical Pathology and
Cytology
Guidelines include a module on ‘Privacy, Confidentiality, and
Security’, which states that system must comply with national
and state privacy regulations and is determined by the Privacy
Act 1988 that regulates how personal information is handled
and includes 13 Australian Privacy Principles [43]
Spain 2021: The Spanish Society of Pathology – White
Paper 2021 of the Pathological Anatomy in
Spain
Guidelines include acknowledgement that ‘The storage system of
digital preparations must be based on open solutions and in
international standards…. which will facilitate compliance with
the Regulation GDPR’ [44]
South Korea 2020: Korean Society of Pathologists (KSP) –
Recommendations for pathological practice
using DP
The guidelines include ‘strict technical measures must be in place
to ensure information security and protect personal information
regardless of the type of terminal being used. Therefore,
measures are needed to ensure that transmitted data are not
easily released outside the network and that transmitted
metadata do not contain personal information to minimise the
risk to personal data even if a data leak was to occur’ [21]
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Co-operative (NPIC), and to membership of The Path-
ological Society of Great Britain and Northern Ireland
and the British Division of the International Academy
of Pathology (BDIAP). The survey was voluntary with
no incentives offered. The survey link remained active
between 14 July 2020 and 6 September 2020 and was
closed only after several reminders had been sent out;
only a few additional responses were gathered. The
responses were automatically collected by the
‘SurveyMonkey’ platform which has mechanisms to
prevent duplication by individuals.
Survey responses were analysed using descriptive
statistics. Inductive analysis of free text answers (sup-
plementary material, Appendix S1 – Questions 20 and
22) was performed using open coding with a final cod-
ing frame developed specifically for this study. Both
sections were coded together and went through two
independent rounds of open coding to determine the
relevant themes. The codes were then cross referenced
to determine the following four main meta-categories:
Governing Data, Validating Data, Ownership and
Third-Party Access, and Inclusivity and Transparency.
Ambiguous and uncategorised comments were not
reported. This manuscript has been prepared in accor-
dance with the CHERRIES guidelines [56].
Results
Response
In total, we received 198 responses including 194 his-
topathologists. Three advanced biomedical scientists
and one clinical scientist also completed the survey,
although it was stated that the survey was targeted at
histopathologists specifically. As these responses rep-
resented only 2% of the overall responses, they were
included in the analysis and we postulate that they rep-
resent scientists who use DP in their role. There was
an overall completion rate of 79% with minor varia-
tions in response rates to individual questions having
been indicated.
Consultants and specialty doctors with >20 years of
clinical experience were the most common responders
(35%, 70/198). Most respondents were based in
England, working in the NHS tertiary referral centres
in NHS posts with no funded academic time (Table 2).
The most common experience with DP was ‘External
Quality Assurance (EQA)’ (82%, 160/196), followed
by ‘Teaching or training’ (72%, 142/196). The most
common experience with consultants was ‘EQA’
(93%, 136/146), whereas for trainees it was ‘Teaching
or training’ (94%, 44/47) (Table 2). Forty-three
Table 2. Summary of respondents – grade, region, current post,
and current centre.
Question Responses













Trainee histopathologist 24% (47/198)







Northern Ireland 3% (6/198)
Question 3. Current post
NHS post, no funded academic time 76% (149/195)
NHS post, including some funded
academic time
11% (22/195)
Academic post including some funded
NHS time
11% (21/195)
Academic post, no funded NHS time 2% (3/195)
Question 4. Current centre
NHS – district general hospital 30% (59/198)
NHS – tertiary referral centre 35% (70/198)
NHS centre and university academic
department
31% (61/198)
University academic department 4% (7/198)
Private laboratory 1% (1/198)
Question 5. Experience with DP
Primary diagnosis
Consultant histopathologist with 5
to >20 years’ experience*
36% (53/146)
Trainee histopathologist 23% (11/47)
Non-histopathologist 0% (0/3)
Second opinion
Consultant histopathologist with 5
to >20 years’ experience*
24% (35/146)
Trainee histopathologist 9% (4/47)
Non-histopathologist 0% (0/3)
Multidisciplinary team meeting
Consultant histopathologist with 5
to >20 years’ experience*
34% (50/146)
Trainee histopathologist 13% (6/47)
Non-histopathologist 67% (2/3)
Research or clinical trials
Consultant histopathologist with 5
to >20 years’ experience*
38% (55/146)
Trainee histopathologist 26% (12/47)
Non-histopathologist 67% (2/3)
(Continues)
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percent (85/198) of respondents had been involved in
research using digital scanned slides; a further 6%
(12/198) were planning to do so in the future. Two
percent (4/196) had no experience in any of the stated
areas of DP.
Training
Eighty-eight percent of respondents (168/190) work-
ing in an NHS centre (190/198) reported having
been offered NHS mandatory training in information
governance, 4% (8/190) had not, and the remaining
7% (14/190) were ‘Not sure’. Nearly a quarter of all
respondents (24%, 48/198) had undertaken addi-
tional training in information governance. Respon-
dents reported attending a variety of additional
online and face-to-face courses over the years
(Table 2).
When asked about their need/desire for training,
39% (27/70) of ‘consultants and specialty doctors with
over 20 years’ experience’ wanted additional training,
whereas approximately half of those with 5–20 years’
experience (51%, 39/77) and trainees (51%, 24/47)
wanted additional training. Those wanting further
training called for this to be specific to DP and to be
delivered in an online Continuing Professional Devel-
opment (CPD)-accredited format. Summary of current
available training, format, and content proposed by
respondents is presented in Table 3.
Confidence in applying guidelines/legislation
Table 4 outlines respondents’ confidence ratings con-
cerning their understanding of policy/legislations and




Consultant histopathologist with 5
to >20 years’ experience*
65% (95/146)
Trainee histopathologist 94% (44/47)
Non-histopathologist 67% (2/3)
EQA
Consultant histopathologist with 5
to >20 years’ experience*
93% (136/146)
Trainee histopathologist 49% (23/47)
Non-histopathologist 33% (1/3)
No experience of specific DP activities
Consultant histopathologist with 5
to >20 years’ experience*
1% (2/146)
Trainee histopathologist 4% (2/47)
Non-histopathologist 0% (0/3)




Planning to undertake research 6% (12/198)










Consultant histopathologist with 5–
10 years’ experience*
8% (7/85)
Trainee histopathologist 22% (19/85)
Non-histopathologist 2% (2/85)
*Or specialty doctor, including training.




‘Personal Information Commissioner Officer
registration’
‘Education for information commissioner
registration and duties under the Data
Protection Act 2018’
‘e-learning as General Medical Council (GMC)
associate’
‘The Oxford University Information
Governance online modules’
‘Part of master’s degree’
‘General Data Protection Regulation (GDPR)
sessions’
‘Information governance training as part of
Good Clinical Practice (GCP) course’
‘Medical Research Council (MRC) module’


















Theory of the legal and ethical considerations
of DP
Application of legislation
Examples including case reports/exemplars
Use of scanned slide image sharing
Anonymising cases – when and how to
Dos and don’ts of DP
Templates/guidelines
Risks and responsibilities
Relevance to development of AI tools
Implications of reporting patient specimens
off site
Use of images in publication and online
education
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(DPA 2018) had the highest confidence ratings [23].
At the other end of the spectrum, respondents were
least confident in their knowledge of the (now defunct)
EU – US Privacy Shield, followed by the NHS
National Data Opt-out [24,29]. Regarding ethical
guidance, all three groups reported predominantly
‘Not at all confident’ in their understanding of all three
guidelines. There seemed to be higher confidence
Table 4. Response rates on confidence rating for legal (Question 9) and ethical guidance (Question 10); overall, comparing those with
additional training to those without and comparing those involved in research to those not involved in research (excludes those






















GDPR 16 23 27 24 8 1 196 Overall
13 4 28 30 20 4 46 Additional training
17 29 27 22 5 0 150 Without additional training
8 18 27 34 12 1 83 Involved in research
24 25 27 18 6 1 101 Not involved in research
DPA 2018 19 22 22 25 10 2 197 Overall
15 13 21 28 19 4 47 Additional training
21 25 27 24 7 1 150 Without additional training
14 17 20 36 12 1 84 Involved in research
23 28 22 17 9 2 101 Not involved in research
Health and Social
Act 2018
38 20 15 12 5 9 195 Overall
30 17 20 15 13 4 46 Additional training
41 21 13 11 3 11 149 Without additional training
33 16 17 17 6 12 83 Involved in research
44 22 13 8 5 8 100 Not involved in research
EU – US Privacy
Shield
57 8 8 5 2 20 197 Overall
43 9 21 9 2 17 47 Additional training
62 8 4 4 1 21 150 Without additional training
50 8 11 8 0 23 84 Involved in research
63 7 7 3 3 18 101 Not involved in research
NHS Data Opt-Out 46 20 9 10 3 12 196 Overall
30 26 15 11 9 9 46 Additional training
51 18 7 10 1 13 150 Without additional training
37 24 7 13 4 14 83 Involved in research




29 17 15 27 7 7 198 Overall
21 17 13 27 13 10 48 Additional training
31 17 15 27 5 5 150 Without additional training
20 16 16 32 8 7 85 Involved in research






57 8 7 4 2 23 198 Overall
42 8 10 8 4 27 48 Additional training
61 7 6 2 1 22 150 Without additional training
48 9 9 4 4 26 85 Involved in research
64 7 5 4 1 20 101 Not involved in research
NHSX: AI: How to
Get it Right.
2019
59 6 5 4 1 26 198 Overall
38 10 8 8 4 31 48 Additional training
66 4 3 3 0 24 150 Without additional training
51 7 7 7 2 26 85 Involved in research






62 7 3 4 0 25 198 Overall
48 8 4 8 0 31 48 Additional training
66 6 3 2 0 23 150 Without additional training
55 8 5 6 0 26 85 Involved in research
68 5 2 2 0 24 101 Not involved in research
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levels for legislation (General Data Protection Regula-
tion [GDPR] and DPA 2018) compared to ethical
guidance [6]. Comparing responses of those who had
or had not received additional training revealed confi-
dence ratings were higher across respondents who had
undergone additional training.
Understanding of the UK legislation and
application for REC approval
Forty-one percent (82/198) of respondents selected ‘I
do not know’ in connection with circumstances where
the use of digital scanned slide images would fall
under relevant legislation (i.e. GDPR and DPA 2018).
Approximately one-third of research active respon-
dents (31%, 26/85) stated that they did not know when
a particular use is covered by legislation versus 50%
(50/101) of non-researchers. The responses are
summarised in Table 5.
With regard to the Research Ethics Committee
(REC), we asked under which circumstances would
one not require REC approval for the use of digital
images. The majority of respondents answered ‘Diag-
nostic reporting’ (84%), ‘Teaching or training’ (82%),
‘Audit’ (81%), and ‘In an EQA’ (80%). Five percent
responded that ‘No REC approval’ was required for
any of the proposed activities (Figure 1).
Consent
Forty percent (79/197) of all respondents stated ‘I do
not know’ when asked if there was a statement on the
consent procedure/investigation form in their NHS
Trust for the use of data and/or tissue in research.
Research active respondents were more familiar with
this statement as would be expected as it is of less rel-
evance to non-research active pathologists. Only 25%
(21/85) of those undertaking research responded with
‘I do not know’ compared to 51% (52/101) of those
not undertaking research. Interestingly, 6% (12/197) of
overall respondents reported that there was no such
statement.
When asked how confident respondents were in
their understanding and interpretation of the appropri-
ate use of consent in connection with scanned slide
images in research, 47% (93/198) were ‘Not confident
at all’ and only 2% (4/198) were ‘Completely confi-
dent’. Fewer research active respondents reported feel-
ing ‘Not at all confident’ (26%, 22/85) compared with
non-research active respondents (64%, 65/101). These
findings are summarised in Figure 2.
Data sharing
Six percent (11/198) of all respondents had shared
images outside of the EU and 7% (14/197) with indus-
try, both for the purpose of research. On the issue of
public awareness of data sharing with industry, 68%
(133/195) of respondents thought that the public were
‘Not at all aware’ that anonymous data could be
shared with industry. Two percent (3/195) thought
they were ‘Completely aware’.
Digitalisation of pathology
At the end of the e-survey, we provided respondents
with the opportunity to comment on the digitalisation
Table 5. Response rates (Question 13) when asked, ‘when would
the use of digital scanned slide images fall under the relevant UK
data protection legislation (General Data Protection Regulation
and Data Protection Act)? (Please tick all that apply)’.
Response rate
Overall
‘It always does’ 22% (44/198)
‘If there is a patient name on the slide label’ 35% (69/198)
‘If there is a histology (accession) number on the
slide’
25% (50/198)
‘The slide is fully anonymised (link to the case
permanently broken)’
6% (11/198)
‘The slide is pseudonymised (personal identifiers are
removed, but a link or key to identify the case
remains)’
23% (46/198)
‘I do not know’ 41% (82/198)
+/ Research
Have undertaken Digital Pathology research and ‘It
always does’
26% (22/85)
Have NOT undertaken Digital Pathology research and
‘It always does’
20% (20/101)
Have undertaken Digital Pathology research and ‘I do
not know’
31% (26/85)
Have NOT undertaken Digital Pathology research and
‘I do not know’
50% (50/101)
Involved in research
‘If there is a patient name on the slide label’ 39% (33/85)
‘If there is a histology (accession) number on the
slide’
29% (25/85)
‘The slide is fully anonymised (link to the case
permanently broken)’
5% (4/85)
‘The slide is pseudonymised (personal identifiers are
removed, but a link or key to identify the case
remains)’
31% (26/85)
Not involved in research
‘If there is a patient name on the slide label’ 31% (31/101)
‘If there is a histology (accession) number on the
slide’
22% (22/101)
‘The slide is fully anonymised (link to the case
permanently broken)’
7% (7/101)
‘The slide is pseudonymised (personal identifiers are
removed, but a link or key to identify the case
remains)’
17% (17/101)
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of pathology. Analysis of their comments revealed
four main themes: (1) governing data, (2) validating
data, (3) Ownership and third-party access, and
(iv) inclusivity and transparency, with comments about
governing data generating nearly 10 times more than
anything else.
Governing data
Respondents commented on the need to maintain
patient confidentiality and/or anonymity, if and when
consent was needed and the need for data security
(most notably, whether images were protected against
hacking, breaches, or data loss during storage, transfer,
or while working from home). Finally, this theme
contained comments about the lack of, and need for,
training on DP information governance.
Validating data
Respondents noted concerns around the risks and bene-
fits of DP or AI-driven diagnosis compared to tradi-
tional histopathology. Salient risks identified were the
possibility for errors and misdiagnoses, the mixing up
of slides, reproducibility of diagnosis, cost effectiveness
of the new digital system, and the effects of
digitalisation on pathologists’ labour or behaviour.
Regarding the latter, job loss, outsourcing, new liabili-
ties, and overconfidence in AI were noted as possible
negative outcomes of implementing digital workflows.
Figure 1. The percentage response rates to Question 14: ‘Which of the following activities, using digital scanned slides/platform, would
you NOT require Research Ethics Committee (REC) approval for? (Please tick all that apply)’.
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Ownership and third-party access
Respondents raised questions about who owns data in
the context of third-party access, along with comments
about the ethical risks of commercialisation and what
constitutes a fair exchange for the sharing of DP data
with for-profit organisations.
Inclusivity and transparency
Respondents commented on the need for transparency
about data uses and the inclusion of the views and
opinions of the public in decisions about these uses.
They suggested patients should be aware of how their
data would be used and that patient preferences should
be taken into consideration.
Discussion
DP has genuine potential to develop an integrated global
pathology community. The COVID-19 pandemic has
catalysed the urgency of DP adoption with the Food and
Drug administration (FDA) relaxing restrictions to facili-
tate remote working for histopathologists and guidance
on remote DP reporting being issued by the RCPath
[57,58]. The growth of interest in DP services highlights
Figure 2. The percentage response rates to Question 15: ‘How confident do you feel in your understanding and interpretation of the
appropriate use of consent in connection with scanned slide images in research’. *Or specialty doctor, including training.
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the urgent action needed to ensure that ethical/legal con-
siderations do not lag behind the technical development.
Our survey has demonstrated that, despite growing DP
use, histopathologists acknowledge a lack of confidence
in their knowledge and understanding of the key issues of
consent, legislation, and ethical guidelines. Although
some of the issues raised are not in the domain for the
practicing histopathologist, many are. It is important those
working directly with the images are mindful that differ-
ent governance considerations are required depending on
the intended use. According to respondents’ experiences,
there is a lack of resources/training available to support
histopathologists in navigating these areas (Table 3).
There is a paucity of specific guidance on the legal
and ethical issues in the context of diagnostic
DP. RCPath has professional guidance which ‘aims to
give pragmatic and specific guidance on validation and
verification of DP for clinical use’ and the focus is to
assist the introduction of DP for primary diagnosis while
maintaining safety [22]. Therefore, its purpose is not for
research guidance or future applications and ethics falls
outside of its remit. It includes a brief general legal sec-
tion, highlighting the complex nature of such issues and
advises involvement of information governance officers.
It is important that support resources are highlighted,
although an awareness of this area helps people to under-
stand when it is appropriate to seek further help.
Globally, there are numerous country-specific guide-
lines for the implementation and use of DP, at times
more framed in the context of telepathology (Table 1).
The issues of data governance and cybersecurity are
raised, although often only discussed superficially in
the context of implementation rather than specific day-
to-day guidance and not always extended to alternative
uses for the data beyond diagnostic reporting.
With regard to ethical guidance for diagnostic DP, the
RCPath currently has no specific guidelines. However,
focusing on the use of DP for AI development, there is a
current drive by the UK Government to ‘create an eco-
system that ensures we get the use of AI “right” in health
care’ through their development of NHSX [6]. A 2019
report explored a novel governance framework
emphasising the softer ethical considerations of ‘should
versus should not’ in the development of AI solutions as
well as legislative regulations of ‘could versus could not’.
It integrates the 2018 Code of Conduct for Data-Driven
Health and Care Technology from the Department of
Health and Social Care, which aims to promote the devel-
opment of AI with the Nuffield Council on Bioethics’
Principles for Data Initiatives [6,19,59]. Although the
above guidance exists, it is not specific to DP but AI,
however the majority of our respondents were
unaware of it.
More specific ethical guidance is available in
Canada, which has a clearly established WSI workflow
integrated with telepathology and a specific ‘Code of
ethics for storage and transmission of electronic labo-
ratory data’ [40]. Additionally, in 2005, updated in
2013, the Canadian Standards Association (CSA)
developed a voluntary code based on the work of the
‘Guidelines Governing the Protection of Privacy and
Transborder Flows of Personal Data’, created by the
international ‘Organization for Economic Cooperation
and Development (OECD)’. This has been endorsed
by many Canadian companies as the national standard
on privacy protection [39].
Understanding and implementing guidelines depend
on background knowledge of the area. The acquisition of
even a background level of understanding of these topics
appears to be limited. From the authors’ experience,
available courses include generic governance/GDPR,
with content not directly applicable to pathology.
The GDPR is legislation in force in the EU for the
processing of personal data, either within the EU or
such data related to people in the EU [28] (supplemen-
tary material, Appendix S1 – Question 9). The DPA
2018 is the UK’s implementation of the GDPR (sup-
plementary material, Appendix S1 – Question 9) [23].
Under these regulations, personal data (‘information
related to an identified or identifiable living individ-
ual’) is classed as special category personal data when
it includes health data [23,28]. The application of the
GDPR in the context of DP research is dependent on
the data being processed, e.g. fully anonymised data
does not fall under the ambit of the GDPR, whereas
pseudonymised data may [28].
In terms of our questionnaire (supplementary mate-
rial, Appendix S1 – Question 13), the use of digital
scanned slides images falls under the relevant UK
data protection legislation if there is (1) a patient
name and potentially (2) a histology (accession) num-
ber on the slide, or (3) the slide is pseudonymised.
We say ‘potentially’ as the ICO is currently undertak-
ing a review of its anonymisation guidance and a first
draft has been shared for consultation [60]. It states
‘Data protection law does not explicitly define “anon-
ymous information”’ [60]. It goes on to state that ‘In
the ICO’s view, the same information can be personal
data to one organisation, but anonymous information
in the hands of another organisation. Its status
depends greatly on its circumstance’ [60]. Once
finalised and published, this new guidance may assist
researchers to navigate this complex area. Until the
guidance is published, a cautious approach is advised,
and local information governance teams should be
consulted.
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According to the NHSX document AI – How to get it
right, the ‘data access stage’ can also cause a lot of con-
fusion, especially in determining the legal basis for
processing data (direct patient care or secondary) and if
their project should be classed as research or not. For
instance, developing a piece of software using medical
data should always be considered as a secondary use
regardless of whether that software is eventually used to
provide direct care to the patient. It should also be
classed as research and having approval obtained from
the Health Research Authority (HRA) [6]. The legal
basis for data processing under the GDPR for AI-based
pathology research when using anonymised images is
not consent as in many other patient settings but often
legitimate interest under Article 6 of the GDPR. Under
certain circumstances, if it is judged that the GDPR/DPA
applies then, in the UK, a data protection impact assess-
ment may need to be completed [28].
In the UK, the Common Law Duty of Confidentiality
guidelines apply to personal information and are sepa-
rate from data protection legislation (supplementary
material, Appendix S1 – Question 9). They state that
information given in confidence must not be shared
with a third party without an individual’s valid consent
(or some other legal basis) [26]. This includes data that
are anonymised as such data would be derived from a
data set that would require consent from a data subject.
There is also the application of the National Data Opt-
Out, which is a service that ‘allows patients to opt out
of their confidential patient information being used for
research and planning’, although this does not apply to
anonymised information [61] (supplementary material,
Appendix S1 – Question 9).
Difficulties interpreting legislation and guidelines
can be compounded for researchers conducting multi-
centre, multi-jurisdictional studies [62]. There is a
drive to develop International Best Practice Guidance
with involvement from the Global Digital Health Part-
nership (GDHP) – a collaboration of world govern-
ments and the WHO [63]. The WHO has also
partnered with the ITU to establish an FG-AI4H with
the aim of identifying opportunities for international
standardisation [6,64].
Along with the appropriate application of legislation
and guidelines, understanding when REC approval is
needed is also essential for DP research. REC approval
is required for any image analysis projects using
patient data and therefore would NOT usually be
required for diagnostic reporting, teaching or training,
audit, service improvement, quality control or quality
assurance, or use in an EQA (supplementary material,
Appendix S1 – Question 14). The UK 2019 State of
the Nation Survey built up a picture of critical issues
surrounding ethics and regulation [6]. It revealed a
50/50 split in whether AI developers sought ethical
approval. The current complex governance framework
and lack of clarity around the development of AI tech-
nologies may be impeding innovation. Indeed, one of
the NHSX’s objectives is to ensure that in all future
funding applications the expectation of ethical compli-
ance is made clear. We acknowledge that some of the
issues in our survey are more relevant to pathologists
undertaking research. However, it is useful for all
pathologists to be aware of them so that data are not
inadvertently used for secondary purposes without the
appropriate permissions.
A final consideration for DP research is the issue of
data sharing. The majority of respondents in our e-survey
felt that the public were unaware that their anonymised
data could potentially be shared with third parties. A
2020 UK survey of 2095 individuals found that 63%
were unaware that the NHS gives third parties access to
data [65]. Research has shown that the sharing of data
can be viewed positively by patients, subject to the
expectation that such data will be used to further the
common good, is transparent, and benefits should be
shared [65]. NHS, academia, and industry partnerships
can bring synergistic skills into a collaboration, as indus-
try often has greater experience of gaining regulatory
approvals, potentially accelerating development to patient
benefit [66]. The NHSX recognises people are neither
aware that information within their health records has
enormous research potential nor how it can be used in
practice [54]. There are significant public concerns that
commercial organisations may harvest and use their
data [6]. Beyond the scope of this paper, there is also the
issue of the NHS being given perpetual fair value for the
use of data.
The focus of the survey was DP rather than AI,
although these fields are inherently linked because WSI
creates the raw data for building algorithms. Some
respondents raised concerns about AI-driven diagnosis,
such as overconfidence in its performance. Algorithm
development faces ethical challenges such as avoiding
bias, maintaining openness about which data sets are
used, and making it as clear as possible to users how an
algorithm works. These challenges again underline the
need for training histopathologists to understand and
explain results from AI tools. It would be prudent to run
this process in parallel with the DP roll out.
It is beyond the scope of this article to provide guid-
ance on specific legal or ethical questions, and we
intend only to present the general background, consid-
erations, and potential issues that may arise in the DP
setting. We also acknowledge that there may be no
clear answer to some questions raised.
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We have emphasised that the governance, legal, and
ethical frameworks underpinning DP are complex and
there is a lack of confidence in these areas. Highlighting
these issues should not hinder the development of DP
but instead help to build solid foundations for a safe and
secure platform for our patients. Histopathologists should
be specifically trained and assisted to help them navigate
these areas. Specific training resources calling attention
to the complexities should be developed to support histo-
pathologists that are utilising DP. Finally, there were
issues raised in this study, such as data com-
mercialisation, cybersecurity, and the role of industry,
which are outside the scope of this article but that clearly
warrant further study in their own right.
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